Page 1

BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2021 Biohit Oyj Half Year Financial Report 11 August 2021 at 9:30 am local time ( EET ) SUMMARY January - June 2021 • Revenue EUR 4.0 million ( EUR 3.0 million ) • Revenue increased by 36 % compared to H1 / 2020 Operative EBITDA EUR -0.2 million ( EUR -1.0 million ) • Cash at the end of the period EUR 1.0 million ( EUR 1.0 million 31 December 2020 ) Fair value of Genetic Analysis AS investment EUR 0.8 million ( EUR 0.8 million 31 December 2020 ) • • Revenue from international operations 97.2 % ( 95.6 % ) of total revenue Equity ratio 78.4 % ( 80.8 % 31 December 2020 ) BIOHIT GROUP KEY FIGURES 1-6 / 2021 1-6 / 2020 1-12 / 2020 Revenue ( MEUR ) EBITDA ( MEUR ) Operative EBITDA ( MEUR ) Operating profit / loss ( MEUR ) * 4.0 3.0 7.1 -0.2 -1.0 -1.2 -0.2 -1.0 -1.2 -1.2 -2.0 -3.2 Profit / loss before taxes ( MEUR ) -1.1 -2.3 -3.3 Profit / loss for the period ( MEUR ) -1.1 -2.3 -3.3 Average number of personnel 46 44 45 Number of personnel at the end of the period 48 42 46 Equity ratio ( % ) 78.4 % 81.0 % 80.8 % Earnings per share ( EUR ) , Undiluted -0.07 -0.15 -0.22 Earnings per share ( EUR ) , Diluted -0.07 -0.15 -0.22 Shareholders ' equity per share ( EUR ) 0.51 0.64 0.58 Average number of shares during the period 15,045,593 15,045,593 15,045,593 Number of shares at the end of the period 15,045,593 15,045,593 15,045,593 * In 2017 we capitalized the patent regarding divestment of Biohit Healthcare ( Hefei ) Co. Ltd. which is depreciated EUR 1.5 million annually until end of 2021 . 1